Consensus Disc Medicine, Inc.

Equities

IRON

US2546041011

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:10:03 2026-03-10 am EDT			5-day change	1st Jan Change
64.34 ^USD	+0.16%		+0.33%	-18.69%

Feb. 27	Disc Medicine's board approves restructuring plan	RE
Feb. 26	Disc Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Evolution of the Average Target: Disc Medicine, Inc.

Evolution of the Target Price: Disc Medicine, Inc.

Changes in Analyst Recommendations: Disc Medicine, Inc.

a42bebb212a0fceede89d18e53f82645.nzydB-09-BumdGFB3wAGU_MHymCgZFw2ykcPjVXrwOs.zkvLRIhfijblASwNljh2EJZun1nCImhhvmpX5DyY9onVRPx03VW6bMQwIA~0349cc6b24c2d8bf783fd5041f4d09a2

Analysts' recommendations: Disc Medicine, Inc.

Feb. 17	Disc Medicine's Multiple Catalysts Provide Runway Despite Bitopertin Delay, Morgan Stanley Says	MT
Feb. 17	Wedbush Adjusts Price Target on Disc Medicine to $88 From $110, Maintains Outperform Rating	MT
25-10-30	Disc Medicine's Outlook Strengthens After Financing and Pipeline Update, Morgan Stanley Says	MT
25-10-30	Morgan Stanley Raises Price Target on Disc Medicine to $115 From $90, Keeps Overweight Rating	MT
25-10-20	Disc Medicine Provides Update on Cash Position, Hematology Portfolio	MT
25-10-20	Disc Medicine provides update on hematology portfolio	RE
25-10-17	Disc Medicine's Bitopertin Could See US FDA Approval by Early February 2026, Wedbush Says	MT
25-10-17	Top Midday Gainers	MT
25-10-17	Disc Medicine Shares Surge After FDA Grants Priority Voucher for EPP Drug	DJ
25-10-17	Wedbush Adjusts Price Target on Disc Medicine to $110 From $90, Maintains Outperform Rating	MT
25-10-16	Disc Medicine Gets FDA Commissioner's National Priority Voucher for Drug Candidate	MT
25-09-30	Disc Medicine, Inc. Announces Submission of New Drug Application to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria	CI
25-07-21	Truist Securities Initiates Coverage on Disc Medicine With Buy Rating, $86 Price Target	MT
25-02-27	TD Cowen Initiates Coverage on Disc Medicine With Buy Rating	MT
25-01-21	Wedbush Raises Price Target on Disc Medicine to $90 From $83, Keeps Outperform Rating	MT
24-11-12	Wedbush Raises Disc Medicine Price Target to $83 From $75, Maintains Outperform Rating	MT
24-11-05	Morgan Stanley Upgrades Disc Medicine to Overweight From Equalweight, Price Target is $85	MT
24-11-04	Wedbush Adjusts Disc Medicine Price Target to $75 From $60, Maintains Outperform Rating	MT
24-10-16	Scotiabank Initiates Disc Medicine at Sector Outperform	MT
24-08-22	Wells Fargo Initiates Disc Medicine at Overweight With $75 Price Target	MT
24-06-17	BMO Capital Adjusts Price Target on Disc Medicine to $70 From $50, Maintains Outperform Rating	MT
24-06-14	Wedbush Raises Disc Medicine Price Target to $57 From $43, Maintains Outperform Rating	MT
24-04-08	Stifel Raises Price Target on Disc Medicine to $73 From $71, Keeps Buy Rating	MT
24-04-02	Leerink Partners Cuts Price Target on Disc Medicine to $65 From $77, Keeps Outperform Rating	MT
24-04-02	Lifesci Capital Cuts Price Target on Disc Medicine to $48 From $82, Keeps Outperform Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	DISC MEDICINE, INC.					+55.95%
	LONZA GROUP AG					+36.2%
	BEONE MEDICINES AG					+35.53%
	CELLTRION, INC.					+24.36%
	IQVIA HOLDINGS INC.					+32.95%
	REVOLUTION MEDICINES, INC.					+29.62%
	ASCENDIS PHARMA A/S					+19.06%
	MEDPACE HOLDINGS, INC.					+2.31%
	EUROFINS SCIENTIFIC SE					+12.89%
	IONIS PHARMACEUTICALS, INC.					+24.6%
	Average					+27.35%
	Weighted average by Cap.					+28.19%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

64.23USD

Average target price

100.17USD

Spread / Average Target

+55.95%

High Price Target

128.00USD

Spread / Highest target

+99.28%

Low Price Target

75.00USD

Spread / Lowest Target

+16.77%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Wedbush
Morgan Stanley
Truist Securities
TD Cowen
Scotiabank
BMO Capital
Stifel Nicolaus
LifeSci Capital
Leerink Partners
Raymond James
HC Wainwright
Cantor Fitzgerald
SVB Securities LLC